JP2017516855A - 特定のタンパク質キナーゼ阻害剤 - Google Patents

特定のタンパク質キナーゼ阻害剤 Download PDF

Info

Publication number
JP2017516855A
JP2017516855A JP2017514769A JP2017514769A JP2017516855A JP 2017516855 A JP2017516855 A JP 2017516855A JP 2017514769 A JP2017514769 A JP 2017514769A JP 2017514769 A JP2017514769 A JP 2017514769A JP 2017516855 A JP2017516855 A JP 2017516855A
Authority
JP
Japan
Prior art keywords
cyclopentyl
amino
pyridin
carboxamide
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017514769A
Other languages
English (en)
Japanese (ja)
Inventor
ワン，ウェイボー
ジャオ，シンドン
リ，トンシャン
ティエン，チャン
ジャン，ホアジエ
タン，ハオハン
ワン，シャンロン
リウ，チーホン
リ，ジーフ
ジャン，ウェイペン
チェン，ジーファン
ジャン，リーファ
リウ，イエンシン
リンフー，リ
リン，ミン
スン，ジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Fochon Pharmaceutical Co Ltd
Original Assignee
Chongqing Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Fochon Pharmaceutical Co Ltd filed Critical Chongqing Fochon Pharmaceutical Co Ltd
Publication of JP2017516855A publication Critical patent/JP2017516855A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
JP2017514769A 2014-05-28 2015-05-27 特定のタンパク質キナーゼ阻害剤 Pending JP2017516855A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003626P 2014-05-28 2014-05-28
US62/003,626 2014-05-28
PCT/CN2015/079910 WO2015180642A1 (en) 2014-05-28 2015-05-27 Certain protein kinase inhibitors

Publications (1)

Publication Number Publication Date
JP2017516855A true JP2017516855A (ja) 2017-06-22

Family

ID=54698110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017514769A Pending JP2017516855A (ja) 2014-05-28 2015-05-27 特定のタンパク質キナーゼ阻害剤

Country Status (13)

Country Link
US (1) US10087195B2 (enExample)
EP (1) EP3149008B8 (enExample)
JP (1) JP2017516855A (enExample)
KR (1) KR101864589B1 (enExample)
CN (2) CN106795179B (enExample)
AU (1) AU2015266492B2 (enExample)
BR (1) BR112016027679B1 (enExample)
CA (1) CA2950330C (enExample)
DK (1) DK3149008T3 (enExample)
ES (1) ES2715462T3 (enExample)
MX (1) MX381487B (enExample)
RU (1) RU2671494C2 (enExample)
WO (1) WO2015180642A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538042A (ja) * 2019-06-18 2022-08-31 ベイジン、ベニコール、バイオテック、カンパニー、リミテッド Ｃｄｋキナーゼ阻害剤

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106188060A (zh) 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
WO2017114351A1 (en) * 2015-12-27 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
WO2017193872A1 (en) * 2016-05-07 2017-11-16 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
CA3028751A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
EP3505519B1 (en) * 2016-11-11 2022-01-05 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
CN107312006B (zh) * 2017-06-28 2019-11-15 郑州大学第一附属医院 吡咯并嘧啶类衍生物及其应用
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
MA51846A (fr) 2018-02-15 2021-04-21 Nuvation Bio Inc Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN111566101B (zh) 2018-04-24 2023-08-11 上海海雁医药科技有限公司 Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN119013030A (zh) * 2022-01-25 2024-11-22 金耐特生物制药公司 Cdk4/6激酶的抑制剂
CN116836177A (zh) * 2022-09-28 2023-10-03 锦州奥鸿药业有限责任公司 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501744A (ja) * 2004-06-09 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾロピリミジン
JP2009538341A (ja) * 2006-05-26 2009-11-05 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン化合物およびそれらの使用
JP2011503115A (ja) * 2007-11-15 2011-01-27 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド Ｎ含有複素環式化合物
JP2012500785A (ja) * 2008-08-22 2012-01-12 ノバルティス アーゲー Ｃｄｋ阻害剤としてのピロロピリミジン化合物
JP2013508354A (ja) * 2009-10-22 2013-03-07 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー 蛋白質キナーゼ阻害活性を有する２，７−置換されたチエノ［３，２−ｄ］ピリミジン化合物
JP2013519707A (ja) * 2010-02-19 2013-05-30 ノバルティス アーゲー Ｃｄｋ４／６阻害剤としてのピロロピリミジン化合物
WO2013150036A1 (en) * 2012-04-03 2013-10-10 Sanofi Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
JP2013542257A (ja) * 2010-11-10 2013-11-21 ノバルティス アーゲー ７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７ｈ−ピロロ［２，３−ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413378A (en) * 2002-09-23 2004-08-01 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501744A (ja) * 2004-06-09 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾロピリミジン
JP2009538341A (ja) * 2006-05-26 2009-11-05 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン化合物およびそれらの使用
JP2011503115A (ja) * 2007-11-15 2011-01-27 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド Ｎ含有複素環式化合物
JP2012500785A (ja) * 2008-08-22 2012-01-12 ノバルティス アーゲー Ｃｄｋ阻害剤としてのピロロピリミジン化合物
JP2013508354A (ja) * 2009-10-22 2013-03-07 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー 蛋白質キナーゼ阻害活性を有する２，７−置換されたチエノ［３，２−ｄ］ピリミジン化合物
JP2013519707A (ja) * 2010-02-19 2013-05-30 ノバルティス アーゲー Ｃｄｋ４／６阻害剤としてのピロロピリミジン化合物
JP2013542257A (ja) * 2010-11-10 2013-11-21 ノバルティス アーゲー ７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７ｈ−ピロロ［２，３−ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法
WO2013150036A1 (en) * 2012-04-03 2013-10-10 Sanofi Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZIFICSAK, CRAIG A. ET AL.: "Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, no. 1, JPN6017048063, 2012, pages 133 - 137, ISSN: 0003702720 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538042A (ja) * 2019-06-18 2022-08-31 ベイジン、ベニコール、バイオテック、カンパニー、リミテッド Ｃｄｋキナーゼ阻害剤
JP7369798B2 (ja) 2019-06-18 2023-10-26 ベイジン、ベニコール、バイオテック、カンパニー、リミテッド Ｃｄｋキナーゼ阻害剤

Also Published As

Publication number Publication date
DK3149008T3 (en) 2019-04-01
EP3149008A1 (en) 2017-04-05
RU2671494C2 (ru) 2018-11-01
KR101864589B1 (ko) 2018-07-04
CN106795179A (zh) 2017-05-31
EP3149008B8 (en) 2019-03-06
AU2015266492A1 (en) 2017-01-19
ES2715462T3 (es) 2019-06-04
EP3149008A4 (en) 2018-01-17
RU2016151315A3 (enExample) 2018-07-02
MX381487B (es) 2025-03-12
CA2950330A1 (en) 2015-12-03
KR20170023872A (ko) 2017-03-06
WO2015180642A1 (en) 2015-12-03
CN106795179B (zh) 2019-09-17
CN110372720A (zh) 2019-10-25
BR112016027679B1 (pt) 2022-10-25
AU2015266492B2 (en) 2017-11-02
RU2016151315A (ru) 2018-07-02
CA2950330C (en) 2019-04-30
US20170267696A1 (en) 2017-09-21
BR112016027679A2 (enExample) 2017-08-15
CN110372720B (zh) 2021-03-05
EP3149008B1 (en) 2018-12-12
US10087195B2 (en) 2018-10-02
MX2016015565A (es) 2017-07-04

Similar Documents

Publication Publication Date Title
KR101864589B1 (ko) 특정한 단백질 키나아제 억제제
US10022374B2 (en) Certain protein kinase inhibitors
AU2012311504B2 (en) Pyrazolo[4,3-C]pyridine derivatives as kinase inhibitors
WO2015188777A1 (en) Certain protein kinase inhibitors
AU2013344049A1 (en) ALK kinase inhibitors
WO2017133701A1 (en) Certain protein kinase inhibitors
WO2015091584A1 (en) Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
US10328060B2 (en) Certain protein kinase inhibitors
JP2022532145A (ja) 置換ベンズイミダゾロン化合物
EP3750885A1 (en) Compound having bet inhibitory activity and preparation method and use therefor
JP2023551272A (ja) ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途
CN108137580A (zh) 作为激酶抑制剂的稠合的吡啶衍生物
HK1218119B (en) Certain protein kinase inhibitors
HK1240216B (zh) 蛋白激酶抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180904